Pasithea Therapeutics Corp.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | -0.45 | -0.12 | +73.33% |
| 2026-03-30 | -0.18 | -0.89 | -394.44% |
| 2023-08-11 | -3.40 | -2.84 | +16.41% |
| 2023-05-12 | -3.40 | -2.47 | +27.35% |
| 2023-03-30 | -3.40 | -3.81 | -12.18% |
| 2022-11-14 | -2.80 | -3.20 | -14.36% |
| 2022-08-15 | -2.20 | -2.63 | -19.45% |
| 2022-05-16 | -0.40 | -2.09 | -422.50% |
| 2022-03-30 | -1.00 | -2.62 | -162.04% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| KTTA | -14.98% | -10.63% | -44.57% | -26.29% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -17.95% | -5.99% | -41.13% | -38.98% |